La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
GlycoMimetics Gestione
Gestione criteri di controllo 2/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Harout Semerjian
Amministratore delegato
US$2.4m
Compenso totale
| Percentuale dello stipendio del CEO | 26.7% |
| Mandato del CEO | 3yrs |
| Proprietà del CEO | 0.04% |
| Durata media del management | 3yrs |
| Durata media del Consiglio di amministrazione | 7.9yrs |
Aggiornamenti recenti sulla gestione
Recent updates
We're A Little Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Rate
Jun 27
GlycoMimetics Can Become A Game Changer In Blood Cancers
Mar 21Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?
Mar 20GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real
Jan 30Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?
Nov 19Will GlycoMimetics (NASDAQ:GLYC) Spend Its Cash Wisely?
Jan 30Here's Why GlycoMimetics (NASDAQ:GLYC) Must Use Its Cash Wisely
Oct 06GlycoMimetics has a new Chief Medical Officer
Sep 06GlycoMimetics GAAP EPS of $0.25 beats by $0.53, revenue of $75K
Aug 03GlycoMimetics (NASDAQ:GLYC) Will Have To Spend Its Cash Wisely
Jun 04GlycoMimetics Positive Data For AML Therapy Increasingly Likely
Mar 16Here's Why We're Watching GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation
Nov 20We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully
Aug 20GlycoMimetics says first patient dosed in investigator-sponsored mid-stage uproleselan study
May 26Here's Why It's Unlikely That GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Will See A Pay Rise This Year
May 12GlycoMimetics EPS beats by $0.04
May 03Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation
Mar 26GlycoMimetics' (NASDAQ:GLYC) Shareholders Are Down 83% On Their Shares
Feb 19GlycoMimetics, Inc. (NASDAQ:GLYC) Insiders Increased Their Holdings
Jan 24How Much Did GlycoMimetics' (NASDAQ:GLYC) CEO Pocket Last Year?
Dec 28New data from GlycoMimetics highlights the efficacy Rivipansel in vaso-occlusive crisis in sickle cell disease
Dec 07Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation
Dec 07The Investment Case For GlycoMimetics
Nov 17Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$39m |
| Mar 31 2024 | n/a | n/a | -US$37m |
| Dec 31 2023 | US$2m | US$638k | -US$37m |
| Sep 30 2023 | n/a | n/a | -US$38m |
| Jun 30 2023 | n/a | n/a | -US$37m |
| Mar 31 2023 | n/a | n/a | -US$42m |
| Dec 31 2022 | US$1m | US$614k | -US$47m |
| Sep 30 2022 | n/a | n/a | -US$54m |
| Jun 30 2022 | n/a | n/a | -US$63m |
| Mar 31 2022 | n/a | n/a | -US$64m |
| Dec 31 2021 | US$3m | US$244k | -US$63m |
Compensazione vs Mercato: La retribuzione totale di Harout ($USD 2.39M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 681.57K ).
Compensazione vs guadagni: La retribuzione di Harout è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Harout Semerjian (54 yo)
3yrs
Mandato
US$2,389,418
Compensazione
Mr. Harout Semerjian serves as Chief Executive Officer, President & Director of GlycoMimetics, Inc., since August 6, 2021. He served as President and Chief Executive Officer of Immunomedics Inc. since Apri...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, President & Director | 3yrs | US$2.39m | 0.039% $ 4.6k | |
| Co-Founder & Director | 21.6yrs | US$96.00k | 0.98% $ 117.5k | |
| Senior VP & CFO | 12.6yrs | US$1.30m | 0.096% $ 11.5k | |
| Senior VP & Chief Medical Officer | 1.9yrs | US$1.15m | 1.06% $ 125.9k | |
| Vice President of Accounting | 5.6yrs | Nessun dato | Nessun dato | |
| General Counsel & Company Secretary | 5.3yrs | Nessun dato | Nessun dato | |
| Senior VP & Chief Commercial Officer | 2.5yrs | Nessun dato | 0.22% $ 25.7k | |
| Senior VP & Chief Business Officer | 1.5yrs | Nessun dato | 0.25% $ 29.8k | |
| Senior Vice President of Technical Operations | less than a year | Nessun dato | Nessun dato |
3.0yrs
Durata media
54yo
Età media
Gestione esperta: Il team dirigenziale di GLYC è considerato esperto (durata media dell'incarico 3 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, President & Director | 3yrs | US$2.39m | 0.039% $ 4.6k | |
| Co-Founder & Director | 21.6yrs | US$96.00k | 0.98% $ 117.5k | |
| Independent Director | 8.4yrs | US$118.50k | 0.15% $ 18.2k | |
| Independent Chairman of the Board | 10.4yrs | US$138.00k | 0.038% $ 4.6k | |
| Independent Director | 7.4yrs | US$100.50k | 0.057% $ 6.8k | |
| Independent Director | 5.8yrs | US$111.00k | 0.0081% $ 971.1 | |
| Independent Director | 7.2yrs | US$105.00k | 0.091% $ 10.8k | |
| Independent Director | 10.1yrs | US$111.00k | Nessun dato |
7.9yrs
Durata media
65yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di GLYC sono considerati esperti (durata media dell'incarico 7.9 anni).